Prothena Corporation plc
PRTA · NASDAQ
Market closed$8.66$0.190000 (+2.24%)After hours $8.66 · 0.00%
Key statistics
Previous close$8.47
Open$8.29
Day high$8.80
Day low$8.28
52-week high$11.80
52-week low$6.24
Market cap453.38M
Volume390.83K
Average volume547.03K
P/E ratio-3.53
Forward P/E—
EPS-2.45
Dividend yield0.00%
Market context
Why it moved
PRTA edged higher amid a broadly cautious market environment, with renewed geopolitical tensions in the Strait of Hormuz and rising oil prices contributing to sector rotation and modest buying interest in biotech and specialty pharma names.
What is happening
Recent company-specific developments and publisher coverage.
ad-hoc-news.de · July 7, 2026Prothena Corp plc updates investors on pipeline progress as neurodegeneration focus deepensThe Global Legal Post · June 19, 2026Biotech company Prothena promotes deputy GC to legal headTradingView · May 26, 2026Prothena 10% Owner Purchased Shares Worth Over $981KBusiness Wire · May 7, 2026Prothena Reports First Quarter 2026 Financial Results and Business HighlightsBusiness Wire · April 27, 2026Prothena Announces Novo Nordisk Obtains Fast Track Designation from the U.S. FDA for Coramitug (PRX004) in ATTR Amyloidosis with CardiomyopathyInvesting.com · April 10, 2026Prothena promotes Kingston, Isaacs to leadership rolesInvesting.com · March 24, 2026H.C. Wainwright reiterates Prothena stock rating on Parkinson’s dataBioSpace · August 28, 2025Prothena’s Alzheimer’s Drug Comes With Familiar Side Effect in Phase I Test Mt Newswire · June 5, 2026Prothena Corp Public Ltd Insider Bought Shares Worth $465,295, According to a Recent SEC Filing Mt Newswire · June 3, 2026Prothena Corp Public Ltd Insider Bought Shares Worth $471,300, According to a Recent SEC Filing Benzinga · May 26, 2026UPDATED: Watching Prothena; Shares Spike Higher, Form4 Filing Shows William P. Scully Bought 100,000 Shares At An Average Price Of $9.81/Share Mt Newswire · May 26, 2026Prothena Insider Bought Shares Worth $981,300, According to a Recent SEC Filing Benzinga · May 8, 2026Citizens Maintains Market Outperform on Prothena Corp, Raises Price Target to $20 Benzinga · May 7, 2026Prothena Corp Q1 EPS $0.60 Beats $(0.34) Estimate, Sales $51.084M Beat $1.010M Estimate Mt Newswire · April 27, 2026Prothena Says Novo Nordisk Gets FDA Fast Track Designation for Coramitug in ATTR-CM Benzinga · April 27, 2026Prothena Announces Coramitug Amyloid Depleter Antibody Receives FDA's Fast Track Designation To Treat ATTR Amyloidosis With Cardiomyopathy